Premium
Second‐by‐second analysis of alpha 7 nicotine receptor regulation of glutamate release in the prefrontal cortex of awake rats
Author(s) -
KonradssonGeuken Åsa,
Gash Clelland R.,
Alexander Kathleen,
Pomerleau Francois,
Huettl Peter,
Gerhardt Greg A.,
Bruno John P.
Publication year - 2009
Publication title -
synapse
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.809
H-Index - 106
eISSN - 1098-2396
pISSN - 0887-4476
DOI - 10.1002/syn.20693
Subject(s) - glutamate receptor , nicotine , chemistry , nicotinic agonist , pharmacology , nmda receptor , agonist , kynurenine , neuroscience , biochemistry , medicine , receptor , biology , amino acid , tryptophan
These experiments utilized an enzyme‐based microelectrode selective for the second‐by‐second detection of extracellular glutamate to reveal the α7‐based nicotinic modulation of glutamate release in the prefrontal cortex (PFC) of freely moving rats. Rats received intracortical infusions of the nonselective nicotinic agonist nicotine (12.0 mM, 1.0 μg/0.4 μl) or the selective α7 agonist choline (2.0 mM/0.4 μl). The selectivity of drug‐induced glutamate release was assessed in subgroups of animals pretreated with the α7 antagonist, α‐bungarotoxin (α‐BGT, 10 μM), or kynurenine (10 μM) the precursor of the astrocyte‐derived, negative allosteric α7 modulator kynurenic acid. Local administration of nicotine increased glutamate signals (maximum amplitude = 4.3 ± 0.6 μM) that were cleared to baseline levels in 493 ± 80 seconds. Pretreatment with α‐BGT or kynurenine attenuated nicotine‐induced glutamate by 61% and 60%, respectively. Local administration of choline also increased glutamate signals (maximum amplitude = 6.3 ± 0.9 μM). In contrast to nicotine‐evoked glutamate release, choline‐evoked signals were cleared more quickly (28 ± 6 seconds) and pretreatment with α‐BGT or kynurenine completely blocked the stimulated glutamate release. Using a method that reveals the temporal dynamics of in vivo glutamate release and clearance, these data indicate a nicotinic modulation of cortical glutamate release that is both α7‐ and non‐α7‐mediated. Furthermore, these data may also provide a mechanism underlying the recent focus on α7 full and partial agonists as therapeutic agents in the treatment of cortically mediated cognitive deficits in schizophrenia. Synapse 63:1069–1082, 2009. © 2009 Wiley‐Liss, Inc.